Many amino acid transporters are solvent carrier proteins, which are membrane transport proteins. In order for cells of all kinds to thrive, including cancerous ones, they need a constant supply of amino acids, which are important for growth and development. Tumor cells exhibit considerable metabolic reprogramming as one of their distinguishing characteristics. A growing number of studies have shown that the Warburg effect is just one of several factors that influence the development and occurrence of cancers and the tumor microenvironment, immunological response, and cell activity in the gained and innate immune systems. Metabolism reprogramming is required for both cancer growth and the induction of efficient immune systems in the tumor microenvironment. The amino acid metabolism of different cells and their interaction with one another influence tumor immunity and therapeutic efficacy in cancer patients. Therefore, amino acid metabolism has received more attention. Amino acid metabolism is extensively involved in regulating the immune response in the tumor microenvironment. Tumor immunotherapy helps the immune system kill tumor cells by targeting specific molecules and abnormal metabolic processes to change the tumor microenvironment. Amino acid metabolizable energy regulates tumor microenvironment and anti-tumor immune response from signal transduction, tumor inflammatory environment, angiogenesis, tumor cell invasion, and metastasis. It is a crucial intervention target in tumor immunotherapy. This review summarizes the most recent developments in amino acid metabolic reprogramming in tumorigenesis and immunotherapy.
| Published in | Biochemistry and Molecular Biology (Volume 7, Issue 1) |
| DOI | 10.11648/j.bmb.20220701.12 |
| Page(s) | 6-12 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Amino Acid Metabolic Reprogramming, Tumor Immunotherapy, Tumorigenesis
| [1] | Warburg O “On the origin of cancer cells”. Science, 123 (3191): 309–323, 1956. |
| [2] | Vander Heiden M G, Cantley LC, and Thompson C B “Understanding the Warburg effect: the metabolic requirements of cell proliferation”. Science, 324 (5930): 1029–1062, 2009. |
| [3] | Faubert B, Solmonson A, and Deberardinis R J “Metabolic reprogramming and cancer progression”. Science, 368 (6487): 5473–5473, 2020. |
| [4] | Eisenberg-Bord M Eisenberg L and Eisenberg-Lern-ErA “Metabolic alterations in the tumor microenvironment and their role in oncogenesis”. Cancer Lett, 484: 65–71, 2020. |
| [5] | Watson M J, Vignali P D A, and Meta Mullett S J “bolic support of tumour-infiltrating regulatory T cells by lactic acid”. Nature, 591 (7851): 645–51, 2021. |
| [6] | Biswas S K “Metabolic reprogramming of immune cells in cancer progression”. Immunity, 43 (3): 435– 484, 2015. |
| [7] | Liu X and Li L Hartman C L “Reprogramming lipid metabolism prevents effector T cell senescence and enhances tumor immunotherapy”. Sci Transl Med, 13 (587): 6314–6314, 2021. |
| [8] | Huangyang P and Simon M C “Hidden features: exploring the non-canonical functions of metabolic enzymes”. Dis Model Mech, 11 (8): 33365–33365, 2018. |
| [9] | Yong C, Stewart G D, and Frezza C “Oncometabolites in renal cancer”. Nat Rev Nephrol, 2020 (3): 156–72. |
| [10] | Vettore L, Westbrook R L, and Tennant D A “New aspects of amino acid metabolism in cancer”. Br J Cancer, 2020 (2): 150–156. |
| [11] | Reinfeld B I and Madden M Z and Wolf M M “Cellpro-grammed nutrient partitioning in the tumour microenvironment”. Nature, 593 (7858): 282–290, 2021. |
| [12] | Miyajima M, Zhang B, and Sugiura Y “Metabolic shift induced by systemic activation of T cells in PD-1-deficient mice perturbs brain monoamines and emotional behavior”. Nat Immunol, 18 (12): 1342–52, 2017. |
| [13] | Makowski L, Chaib M, and Rathmell J C “Immunometabo-lism: from basic mechanisms to translation”. Immunol Rev, 2020 (1): 5–14. |
| [14] | Bahadoran A, Bezavada L, and Smallwood H S “Fueling influenza and the immune response: implications for metabolic reprogramming during influenza infection and immunometabolism”. Immunol Rev, 2020 (1): 140–66. |
| [15] | Wang G Zhang W and Xu Z G “Lactate is a natural suppressor of RLR signaling by targeting MAVS”. Cell, 178 (1): 176–89, 2019. |
| [16] | Certo M, Tsai C H, and Pucino V “Lactate modulation of immune responses in inflammatory versus tumourmicroenviron-ments”. Nat Rev Immunol, 21 (3): 151–61, 2021. |
| [17] | Gong K, Guo G, and Panchani N “EGFR inhibition triggers an adaptive response by coopting antiviral signaling pathways in lung cancer”. Nat Cancer, 2020 (4): 394–409. |
| [18] | Ren W and Y Xia and Chen S “Glutamine metabolism in macro phages: a novel target for obesity/type 2 diabetes”. AdvNutr, 10 (2): 321–351, 2019. |
| [19] | Kato Y, Ozawa S, and Miyamoto C “Acidic extracel-lular microenvironment and cancer”. Cancer Cell Int, 13 (1): 89–89, 2013. |
| [20] | Jung J Zeng and H Horng T “Metabolism as a guiding force for immunity”. Nat Cell Biol, 21 (1): 85–93, 2019. |
| [21] | Wang W and Zou W “Amino acids and their transporters in T cell immunity and cancer therapy”. Mol Cell, 2020 (3): 384–95. |
| [22] | Fernandez-De-Cossio-Diaz J Vazquez A “Limits of aerobic metabolism in cancer cells”. Sci Rep, 7 (1): 13488–13488, 2017. |
| [23] | Zhang J, Pavlova N N, and Thompson C B “Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine”. EMBO J, 36 (10): 1302–1317, 2017. |
| [24] | Newsholme P and Procopio Lima M M “Glutamine and glutamate as vital metabolites”. Braz J Med Biol Res, 36 (2): 153–63, 2003. |
| [25] | Leone R D, Zhao L, and Englert J M “Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion”. Science, 366 (6468): 1013–1034, 2019. |
| [26] | Munn D H, Zhou M, and Attwood JT “Prevention of allogeneic fetal rejection by tryptophan catabolism”. Science, 281 (5380): 1191–1194, 1998. |
| [27] | H Lemos, Huang L, and Prendergast G C “Immune control by amino acid catabolism during tumorigenesis and therapy”. Nat Rev Cancer, 19 (3): 162–75, 2019. |
| [28] | Van Baren N and Van Den Eynde B J “Tryptophandegrading enzymes in tumoral immune resistance”. Front Immunol, 6: 34–34, 2015. |
| [29] | Qian S, M Zhang, and Chen Q, IDO as a drug target for cancer immunotherapy: recent developments in IDO inhibitors discovery [J]. RSC Advances, 2016, 6 (9): 7575-81. |
| [30] | Opitz C A and Sahm Litzenburger U M “An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor”. Nature, 478 (7368): 197–203, 2011. |
| [31] | Cervenka I and Ruas J L Agudelo L Z “Kynurenines: tryptophan’s metabolites in exercise, inflammation, and mental health”. Science, 357 (6349): 9794–9794, 2017. |
| [32] | Sculier J P and Botta I and Bucalau A M “Medical anti-cancer treatment of lung cancer associated with comorbidities: a review”. Lung Cancer, 87 (3): 241– 249, 2015. |
| [33] | H Sui, H Xu, and Ji Q “5-hydroxytryptamine receptor (5-HT1DR) promotes colorectal cancer metastasis by regulating Axin1/beta-catenin/MMP-7 signaling pathway”. Oncotarget, 6 (28): 25975–87, 2015. |
| [34] | Fahrmann J F and Ostrin E J Vykoukal J V “Amino acid oncometabolism and immunomodulation of the tumor microenvironment in lung cancer”. Front Oncol, 10: 276–276, 2020. |
| [35] | Krall A S, Xu S, and Graeber T G “Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor”. Nat Commun, 7 (1): 11457–11457, 2016. |
| [36] | Hope H C, Brownlie R J, and Fife C M “Coordination of asparagine uptake and asparagine synthetase expression modu-lates CD8+ T cell activation”. JCI Insight, 6 (9): 137761–137761, 2021. |
| [37] | Deng L, P Yao, and Li L “p53-mediated control of aspartate-asparagine homeostasis dictates LKB1 activity and modulates cell survival”. Nat Commun, 2020 (1): 1755–1755. |
| [38] | Garcia-Bermudez J Baudrier L and La K “Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumours”. Nat Cell Biol, 20 (7): 775– 81, 2018. |
| [39] | Wei Z and X Liu and Cheng C “Metabolism of amino acids in cancer”. Front Cell DevBiol, 8: 603837– 603837, 2020. |
| [40] | Wang X Zou S and Liu P “Arginine metabolism and deprivation in cancer therapy”. Biomed Pharmacother, 118: 109210–109210, 2019. |
| [41] | Kishton R J, Sukumar M, and Restifo N P “Arginine arms T cells to thrive and survive”. Cell Metab, 24 (5): 647–655, 2016. |
| [42] | Rodriguez P C and Ochoa A C “Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives”. Immunol Rev, 222 (1): 180–91, 2008. |
| [43] | Czystowska-Kuzmicz M Sosnowska A and Nowis D “Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma”. Nat Commun, 10 (1): 3000–3000, 2019. |
| [44] | Steggerda S M and Chen J Bennett M K “Inhibitionofarginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment”. J Immunother Cancer, 5 (1): 101–101, 2017. |
| [45] | Wang Y and Cui S Z “Research prog-ress in immune function of patients with malignant tumors and in cancer immunotherapy”. Chin J Clin Oncol, (13): 876– 885, 2014. |
| [46] | Yao J, Z Du, and Li Z “6-Gingerol as an arginase inhibitor prevents urethane-induced lung carcinogenesis by reprogramming tumor supporting M2 macrophages to M1 phenotype”. Food Funct, 9 (9): 4611–4631, 2018. |
| [47] | Jiang B Jiang H Y and Liu F “Research progress of tumor immune checkpoint therapy”. Modern Oncology, 25 (6): 990–993, 2017. |
| [48] | Boussiotis V A “Molecular and biochemical aspects of the PD-1 checkpoint pathway”. N Engl J Med, 375 (18): 1767–78, 2016. |
| [49] | Patsoukis N, Bardhan K, and Chatterjee P “PD-1 al-ters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation”. Nat Commun, 6 (1): 6692–6692, 2015. |
| [50] | Lim S, Madeira Phillips J B, and Da Silva L “Interplay between immune checkpoint proteins and cellular metabolism”. Cancer Res, 77 (6): 1245–1254, 2017. |
| [51] | Pavasant Issaranggun Na Ayuthaya B. Influence of exogenous IL-12 on human periodontal ligament cells. Springer, Berlin, 2017. |
| [52] | Weichselbaum R R, H Liang, and Deng L “Radiotherapy and immunotherapy: a beneficial liaison”. Nat Rev ClinOncol, 14 (6): 365–79, 2017. |
| [53] | Siska P J and Rathmell J C “T cell metabolic fitness in antitumor immunity”. Trends Immunol, 36 (4): 257– 64, 2015. |
| [54] | Wang W and Green M and Choi J E “CD8+ T cells regulate tumor ferroptosis during cancer immunotherapy”. Nature, 569 (7755): 270–274, 2019. |
APA Style
Safir Ullah Khan, Munir Ullah Khan. (2022). The Role of Amino Acid Metabolic Reprogramming in Tumor Development and Immunotherapy. Biochemistry and Molecular Biology, 7(1), 6-12. https://doi.org/10.11648/j.bmb.20220701.12
ACS Style
Safir Ullah Khan; Munir Ullah Khan. The Role of Amino Acid Metabolic Reprogramming in Tumor Development and Immunotherapy. Biochem. Mol. Biol. 2022, 7(1), 6-12. doi: 10.11648/j.bmb.20220701.12
AMA Style
Safir Ullah Khan, Munir Ullah Khan. The Role of Amino Acid Metabolic Reprogramming in Tumor Development and Immunotherapy. Biochem Mol Biol. 2022;7(1):6-12. doi: 10.11648/j.bmb.20220701.12
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.bmb.20220701.12,
author = {Safir Ullah Khan and Munir Ullah Khan},
title = {The Role of Amino Acid Metabolic Reprogramming in Tumor Development and Immunotherapy},
journal = {Biochemistry and Molecular Biology},
volume = {7},
number = {1},
pages = {6-12},
doi = {10.11648/j.bmb.20220701.12},
url = {https://doi.org/10.11648/j.bmb.20220701.12},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.bmb.20220701.12},
abstract = {Many amino acid transporters are solvent carrier proteins, which are membrane transport proteins. In order for cells of all kinds to thrive, including cancerous ones, they need a constant supply of amino acids, which are important for growth and development. Tumor cells exhibit considerable metabolic reprogramming as one of their distinguishing characteristics. A growing number of studies have shown that the Warburg effect is just one of several factors that influence the development and occurrence of cancers and the tumor microenvironment, immunological response, and cell activity in the gained and innate immune systems. Metabolism reprogramming is required for both cancer growth and the induction of efficient immune systems in the tumor microenvironment. The amino acid metabolism of different cells and their interaction with one another influence tumor immunity and therapeutic efficacy in cancer patients. Therefore, amino acid metabolism has received more attention. Amino acid metabolism is extensively involved in regulating the immune response in the tumor microenvironment. Tumor immunotherapy helps the immune system kill tumor cells by targeting specific molecules and abnormal metabolic processes to change the tumor microenvironment. Amino acid metabolizable energy regulates tumor microenvironment and anti-tumor immune response from signal transduction, tumor inflammatory environment, angiogenesis, tumor cell invasion, and metastasis. It is a crucial intervention target in tumor immunotherapy. This review summarizes the most recent developments in amino acid metabolic reprogramming in tumorigenesis and immunotherapy.},
year = {2022}
}
TY - JOUR T1 - The Role of Amino Acid Metabolic Reprogramming in Tumor Development and Immunotherapy AU - Safir Ullah Khan AU - Munir Ullah Khan Y1 - 2022/03/09 PY - 2022 N1 - https://doi.org/10.11648/j.bmb.20220701.12 DO - 10.11648/j.bmb.20220701.12 T2 - Biochemistry and Molecular Biology JF - Biochemistry and Molecular Biology JO - Biochemistry and Molecular Biology SP - 6 EP - 12 PB - Science Publishing Group SN - 2575-5048 UR - https://doi.org/10.11648/j.bmb.20220701.12 AB - Many amino acid transporters are solvent carrier proteins, which are membrane transport proteins. In order for cells of all kinds to thrive, including cancerous ones, they need a constant supply of amino acids, which are important for growth and development. Tumor cells exhibit considerable metabolic reprogramming as one of their distinguishing characteristics. A growing number of studies have shown that the Warburg effect is just one of several factors that influence the development and occurrence of cancers and the tumor microenvironment, immunological response, and cell activity in the gained and innate immune systems. Metabolism reprogramming is required for both cancer growth and the induction of efficient immune systems in the tumor microenvironment. The amino acid metabolism of different cells and their interaction with one another influence tumor immunity and therapeutic efficacy in cancer patients. Therefore, amino acid metabolism has received more attention. Amino acid metabolism is extensively involved in regulating the immune response in the tumor microenvironment. Tumor immunotherapy helps the immune system kill tumor cells by targeting specific molecules and abnormal metabolic processes to change the tumor microenvironment. Amino acid metabolizable energy regulates tumor microenvironment and anti-tumor immune response from signal transduction, tumor inflammatory environment, angiogenesis, tumor cell invasion, and metastasis. It is a crucial intervention target in tumor immunotherapy. This review summarizes the most recent developments in amino acid metabolic reprogramming in tumorigenesis and immunotherapy. VL - 7 IS - 1 ER -
Information
Email: